South San Francisco, California — March 5, 2026
Tenaya Therapeutics and Alnylam Pharmaceuticals have announced a major research collaboration aimed at discovering and validating new genetic targets for cardiovascular disease therapies, marking a significant step toward next-generation treatments for heart conditions. The partnership combines Tenaya’s advanced capabilities in genetic target identification and validation with Alnylam’s leadership in RNA interference (RNAi) therapeutics, with the potential to generate innovative disease-modifying therapies. Under the agreement, Tenaya will receive up to $10 million in upfront payments, research funding, and potential milestone payments totaling up to $1.13 billion, highlighting the scale and strategic importance of this collaboration for future cardiovascular drug development.
Strategic Collaboration to Discover Novel Genetic Targets
The collaboration focuses on identifying and validating up to 15 novel gene targets linked to cardiovascular disease, one of the leading causes of mortality worldwide. Tenaya will leverage its human genetics-driven discovery platform and integrated research technologies to identify potential therapeutic targets. These targets could lead to the development of new medicines designed to address the underlying biological drivers of heart disease rather than simply managing symptoms.
The collaboration focuses on identifying and validating up to 15 novel gene targets linked to cardiovascular disease, one of the leading causes of mortality worldwide. Tenaya will leverage its human genetics-driven discovery platform and integrated research technologies to identify potential therapeutic targets. These targets could lead to the development of new medicines designed to address the underlying biological drivers of heart disease rather than simply managing symptoms.
Tenaya’s leadership emphasized that the partnership reflects the company’s commitment to rigorous scientific discovery and innovative therapeutic strategies. By combining the strengths of both organizations, the collaboration seeks to accelerate the identification of promising genetic pathways that could ultimately lead to transformational treatments for patients suffering from cardiovascular disorders.
Advertisement
Advanced Genetic Discovery Platforms Driving Innovation
Tenaya’s target discovery platform integrates human genetics, stem cell-derived cardiomyocytes, high-throughput screening technologies, imaging analysis, and machine learning algorithms to identify promising cardiovascular disease targets. These capabilities allow researchers to analyze genetic signals linked to heart disease and rapidly validate potential therapeutic pathways.
The company’s platform also uses engineered human heart tissue models and preclinical in vivo disease models to confirm the biological relevance of newly identified targets. Through this integrated approach, Tenaya has already generated more than 150 potential genetic targets for cardiovascular disease, demonstrating the depth and scalability of its discovery engine.
These technologies have also contributed to Tenaya’s growing pipeline of therapeutic candidates, including TN-201 and TN-401 gene therapies targeting specific genetic causes of cardiomyopathy and TN-301, a small-molecule HDAC6 inhibitor being explored for heart failure and related cardiomuscular diseases. The company’s research strategy focuses on addressing both rare inherited cardiac disorders and broader cardiovascular conditions affecting millions of patients globally.
Transformational Potential for Cardiovascular Drug Development
Heart disease remains one of the most pressing global health challenges, driving the urgent need for new therapies capable of modifying disease progression rather than merely alleviating symptoms. The Tenaya-Alnylam collaboration seeks to address this challenge by focusing on genetic insights that reveal the root causes of cardiovascular conditions.
By combining Tenaya’s genetic discovery capabilities with Alnylam’s RNA interference technology, the collaboration could enable the development of precision therapies designed to silence harmful genes or correct disease pathways at the molecular level. Such approaches are increasingly viewed as the future of medicine, particularly for complex diseases like heart failure, cardiomyopathies, and other cardiovascular disorders.
The potential financial structure of the agreement underscores the long-term ambition of the partnership. With milestone payments reaching up to $1.13 billion if the validated targets lead to approved therapies, the deal reflects both companies’ confidence in the scientific potential of the collaboration and the growing importance of genetic medicine in cardiovascular drug discovery.
As the collaboration progresses, researchers from both organizations will work closely to identify promising gene targets and translate them into innovative therapeutic programs. If successful, the partnership could lead to a new generation of cardiovascular treatments capable of transforming care for patients worldwide.
z
Source: Tenaya Therapeutics Alnylam Pharmaceuticals press release
